In summary, the GLP-1 receptor remains an interesting and noteworthy target for the pharmacotherapy of central nervous system diseases, not only those related to neurodegeneration and substance abuse, but GLP-1RA drugs may also prove effective as adjunctive therapies in the treatment of mood disorders such as depression. Here, GLP1R is linked to major depressive disorder.